SG194755A1 - Pre-fusion rsv f antigens - Google Patents

Pre-fusion rsv f antigens Download PDF

Info

Publication number
SG194755A1
SG194755A1 SG2013081336A SG2013081336A SG194755A1 SG 194755 A1 SG194755 A1 SG 194755A1 SG 2013081336 A SG2013081336 A SG 2013081336A SG 2013081336 A SG2013081336 A SG 2013081336A SG 194755 A1 SG194755 A1 SG 194755A1
Authority
SG
Singapore
Prior art keywords
antigens
fusion
fusion rsv
rsv
relates
Prior art date
Application number
SG2013081336A
Other languages
English (en)
Inventor
Kurt Swanson
Andrea Carfi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46124783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG194755(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG194755A1 publication Critical patent/SG194755A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG2013081336A 2011-05-13 2012-05-14 Pre-fusion rsv f antigens SG194755A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486005P 2011-05-13 2011-05-13
PCT/US2012/037773 WO2012158613A1 (en) 2011-05-13 2012-05-14 Pre-fusion rsv f antigens

Publications (1)

Publication Number Publication Date
SG194755A1 true SG194755A1 (en) 2013-12-30

Family

ID=46124783

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013081336A SG194755A1 (en) 2011-05-13 2012-05-14 Pre-fusion rsv f antigens

Country Status (24)

Country Link
US (8) US20140248314A1 (en:Method)
EP (2) EP2707385B1 (en:Method)
JP (1) JP2014519819A (en:Method)
CN (1) CN103842374A (en:Method)
AU (1) AU2012255971A1 (en:Method)
BR (1) BR112013029169B1 (en:Method)
CA (1) CA2835644C (en:Method)
CY (2) CY1119849T1 (en:Method)
DK (2) DK3275892T3 (en:Method)
ES (2) ES2651143T3 (en:Method)
FR (1) FR23C1046I2 (en:Method)
HR (2) HRP20171703T1 (en:Method)
HU (2) HUE048777T2 (en:Method)
LT (2) LT2707385T (en:Method)
MX (1) MX351011B (en:Method)
NO (1) NO2707385T3 (en:Method)
PL (2) PL3275892T3 (en:Method)
PT (2) PT3275892T (en:Method)
RS (1) RS56748B1 (en:Method)
RU (1) RU2013155485A (en:Method)
SG (1) SG194755A1 (en:Method)
SI (2) SI3275892T1 (en:Method)
SM (1) SMT201700569T1 (en:Method)
WO (1) WO2012158613A1 (en:Method)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
RU2589503C2 (ru) 2010-07-06 2016-07-10 Новартис Аг Липосомы с липидами, имеющими преимущественное значение рка, для доставки рнк
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013114362A (ru) 2010-08-31 2014-10-10 Новартис Аг Пегилированные липосомы для доставки кодирующей иммуноген рнк
ES2862955T5 (en) 2010-10-01 2025-01-29 Modernatx Inc Engineered nucleic acids and methods of use thereof
EP4098324A1 (en) 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
NO2707385T3 (en:Method) 2011-05-13 2018-02-17
CA2840989A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN110511939A (zh) 2011-10-03 2019-11-29 现代泰克斯公司 修饰的核苷、核苷酸和核酸及其用途
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
CA2897752A1 (en) * 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
HUE067333T2 (hu) * 2013-03-13 2024-10-28 The United States Of America As Represented By Prefúziós RSV F fehérjék és ezek felhasználása
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
ES2854673T3 (es) 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10899800B2 (en) * 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
WO2014202570A1 (en) * 2013-06-17 2014-12-24 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
JP6685903B2 (ja) * 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
JP6931327B2 (ja) * 2014-09-23 2021-09-01 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド Ｆｍｄｖ組換えワクチンおよびその使用
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EP3236998A1 (en) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
WO2016118642A1 (en) 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
EP3344290A4 (en) * 2015-08-31 2019-02-27 Technovax, Inc. VACCINE BASED ON VIRUS-LIKE PARTICLES OF HUMAN RESPIRATORY SYNZYTIAL VIRUS (HRSV)
EP4019044A3 (en) * 2015-09-02 2022-08-24 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
WO2017062513A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3368547A4 (en) * 2015-10-29 2019-06-05 Emory University CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS AND METHOD FOR USE THEREOF
MY205060A (en) 2015-12-23 2024-09-30 Pfizer Rsv f protein mutants
WO2017172890A1 (en) 2016-03-29 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use
IL262109B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V vaccine against rsv
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US10953087B2 (en) 2016-05-30 2021-03-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
CN110352072A (zh) * 2016-10-03 2019-10-18 马萨诸塞大学 用于免疫免疫前受试者以抵抗呼吸道合胞病毒(rsv)的方法
CN106432438A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432436A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106749555A (zh) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106749556A (zh) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432435A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106397547A (zh) * 2016-11-28 2017-02-15 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432437A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106518988A (zh) * 2016-11-28 2017-03-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432439A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
MA47790A (fr) * 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
KR20190135017A (ko) * 2017-03-30 2019-12-05 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
HRP20251060T1 (hr) 2017-04-04 2025-11-07 University Of Washington Samosklapajuće proteinske nanostrukture koje prikazuju f proteine paramiksovirusa i/ili pneumovirusa i njihova uporaba
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
EP3624845A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
KR20200018483A (ko) * 2017-06-14 2020-02-19 비로메틱스 아게 호흡기 합포체 바이러스에 대한 방어를 위한 고리형 펩티드
CN111405907B (zh) 2017-08-07 2024-10-01 考尔德生物科技有限公司 构象稳定的rsv预融合f蛋白
MX2020002876A (es) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention Bv Metodo para la induccion segura de inmunidad contra el vsr.
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
CN118955721A (zh) 2018-01-04 2024-11-15 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
KR20250067954A (ko) 2018-02-28 2025-05-15 유니버시티 오브 워싱톤 자기 조립 나노구조 백신
US11623004B2 (en) * 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
EP3781591A1 (en) 2018-04-17 2021-02-24 CureVac AG Novel rsv rna molecules and compositions for vaccination
CN112601545A (zh) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 工艺和疫苗
SG11202104522UA (en) 2018-11-13 2021-05-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
CN110016079B (zh) * 2018-12-18 2019-12-24 珠海泰诺麦博生物技术有限公司 抗呼吸道合胞病毒的中和抗体及其应用
CN109851678A (zh) * 2019-03-07 2019-06-07 苏州宇之波生物科技有限公司 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用
IL317797A (en) 2019-05-30 2025-02-01 Gritstone Bio Inc Modified adenovirus
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
EP4025587A1 (en) 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US20230174587A1 (en) * 2020-04-29 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human metapneumovirus f proteins and their use
WO2021253172A1 (zh) * 2020-06-15 2021-12-23 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
CN113801206B (zh) * 2020-06-15 2024-07-02 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
US20230310570A1 (en) * 2020-08-17 2023-10-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for vaccination of juveniles againstrespiratory syncytial virus infection
CN114213548B (zh) * 2020-12-24 2024-10-29 上海市公共卫生临床中心 同时诱导抗多种病毒的免疫应答的方法
KR20230147156A (ko) 2021-02-19 2023-10-20 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 rsv fb 항원
CN118524848A (zh) * 2021-10-18 2024-08-20 杨克俭 粘膜疫苗、其应用和给药方法
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
CN120475990A (zh) * 2022-11-09 2025-08-12 思齐乐私人有限公司 稳定化疫苗
IL321992A (en) * 2023-01-09 2025-09-01 Univ Texas Human parainfluenza virus 3f proteins stabilized before transfusion
WO2024175040A1 (en) * 2023-02-22 2024-08-29 Everest Medicines (China) Co., Ltd. RSV mRNA VACCINES
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN119462859A (zh) * 2023-08-09 2025-02-18 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、疫苗及其应用
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
CN119569835A (zh) * 2023-09-07 2025-03-07 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
CN117736278B (zh) * 2023-12-25 2025-02-07 英诺特（唐山）生物技术有限公司 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120A (en) 1837-02-10 Mode of constructing steelyard-balances
US4186745A (en) 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE67769T1 (de) 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5639853A (en) 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
DE3878468T2 (de) 1987-12-23 1993-06-09 Upjohn Co Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
JPH0731857B2 (ja) 1988-02-19 1995-04-10 三洋電機株式会社 磁気記録再生装置におけるリール台駆動装置
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ES2131070T3 (es) 1991-03-01 1999-07-16 Minnesota Mining & Mfg 1h-imidazo(4,5-c)quinolin-4-aminas sustituidas en posicion 1 y sustituidas en posicion 2.
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
WO1994015968A1 (en) 1993-01-08 1994-07-21 The Upjohn Company Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
BR9408071A (pt) 1993-11-17 1996-12-24 Om Lab Sa Di-sacarideos de glucosamina processo para sua preparação e composição farmacêutica que compreende os mesmos e seu uso
US5397307A (en) 1993-12-07 1995-03-14 Schneider (Usa) Inc. Drug delivery PTCA catheter and method for drug delivery
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3403233B2 (ja) 1994-01-20 2003-05-06 テルモ株式会社 バルーンカテーテル
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
CA2204254C (en) 1994-11-17 2010-02-16 Stephen Lewis Hart Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
US6090619A (en) 1997-09-08 2000-07-18 University Of Florida Materials and methods for intracellular delivery of biologically active molecules
DE69828801T2 (de) 1997-09-19 2005-07-14 Wyeth Holdings Corp. Peptide, abgeleitet vom angelagerten g-protein des respiratory syncytial virus
EP0980280B1 (en) 1997-10-01 2005-02-09 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
HUP0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
DE69935330T2 (de) 1998-06-30 2007-10-31 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
HK1038695B (en) 1998-10-16 2007-09-14 Glaxosmithkline Biologicals S.A. Adjuvant systems and vaccines
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
ATE276199T1 (de) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
EP1955709B1 (en) 1999-03-26 2012-03-14 Vical Incorporated Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
EP1214053A1 (en) 1999-09-24 2002-06-19 SMITHKLINE BEECHAM BIOLOGICALS s.a. Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one nonionic surfactant
DK1221955T3 (da) 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
EP1313734B1 (en) 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
NZ524717A (en) 2000-09-11 2004-09-24 Chiron Corp Quinolinone derivatives
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US20040161846A1 (en) 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
DE60233049D1 (de) 2001-01-26 2009-09-03 Selexis Sa Matrix-anheftungsregionen und verfahren zu deren verwendung
AU2002245636B2 (en) 2001-03-09 2004-10-14 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
ES2314042T3 (es) 2001-04-17 2009-03-16 Dainippon Sumitomo Pharma Co., Ltd. Derivados nuevos de adenina.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
EP1455700A4 (en) 2001-11-16 2007-02-14 3M Innovative Properties Co METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
AU2002365412B2 (en) 2001-11-27 2008-10-09 Anadys Pharmaceuticals, Inc. 3-Beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
AU2003219839B2 (en) 2002-02-21 2008-02-21 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
SI1499311T1 (sl) 2002-03-29 2010-03-31 Novartis Vaccines & Diagnostic Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze
AU2003227049A1 (en) 2002-04-03 2003-10-13 Akzo Nobel N.V. Viral mutants, manipulated in the furin cleavage sites of glycoproteins
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
KR20050038631A (ko) 2002-08-23 2005-04-27 카이론 코포레이션 글리코겐 신타제 키나제 3의 피롤 기제 억제제
CA2756797C (en) 2002-12-23 2015-05-05 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1675952A2 (en) 2003-10-24 2006-07-05 Selexis S.A. High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US20050222048A1 (en) 2004-03-31 2005-10-06 The Research Foundation Of The City University Of New York Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
KR20070008625A (ko) 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
FR2873378A1 (fr) 2004-07-23 2006-01-27 Pierre Fabre Medicament Sa Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques
CN101014618B (zh) 2004-07-23 2013-01-02 诺华疫苗和诊断有限公司 抗原的寡聚装配多肽
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
GB0422439D0 (en) 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
JP2010522540A (ja) 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
US20100261155A1 (en) 2007-06-06 2010-10-14 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
SG188813A1 (en) 2007-12-24 2013-04-30 Id Biomedical Corp Quebec Recombinant rsv antigens
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
CA2721246A1 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
CA2730737A1 (en) 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
JP2011528222A (ja) 2008-07-18 2011-11-17 アイディー バイオメディカル コーポレイション オブ ケベック キメラ呼吸器合胞体ウイルスポリペプチド抗原
WO2010077712A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
SI2445526T1 (sl) 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
JP5796011B2 (ja) 2009-06-24 2015-10-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
CA2830901A1 (en) 2011-03-22 2012-09-27 Mucosis B.V. Immunogenic compositions in particulate form and methods for producing the same
NO2707385T3 (en:Method) 2011-05-13 2018-02-17
ES2395677B1 (es) 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP3207146B1 (en) 2014-10-15 2021-09-29 Amgen Inc. Promoter and regulatory elements for improved expression of heterologous genes in host cells
KR20190135017A (ko) 2017-03-30 2019-12-05 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도

Also Published As

Publication number Publication date
EP3275892B1 (en) 2020-01-08
BR112013029169A2 (pt) 2017-09-19
US20140248314A1 (en) 2014-09-04
CY1122826T1 (el) 2021-05-05
HRP20200451T1 (hr) 2020-06-26
PT2707385T (pt) 2017-12-19
US20220332767A1 (en) 2022-10-20
ES2651143T3 (es) 2018-01-24
DK2707385T3 (da) 2017-11-20
HRP20171703T1 (hr) 2017-12-15
WO2012158613A1 (en) 2012-11-22
FR23C1046I2 (fr) 2025-01-03
EP2707385B1 (en) 2017-09-20
DK3275892T3 (da) 2020-04-06
PL3275892T3 (pl) 2020-09-07
MX2013013133A (es) 2014-02-20
SI2707385T1 (en) 2018-01-31
PT3275892T (pt) 2020-04-08
RU2013155485A (ru) 2015-06-20
ES2782119T3 (es) 2020-09-10
US20230287056A1 (en) 2023-09-14
CY1119849T1 (el) 2018-06-27
HUE048777T2 (hu) 2020-08-28
SI3275892T1 (sl) 2020-06-30
PL2707385T3 (pl) 2018-03-30
EP3275892A3 (en) 2018-03-14
US20240239845A1 (en) 2024-07-18
US20210269489A1 (en) 2021-09-02
BR112013029169B1 (pt) 2021-09-28
MX351011B (es) 2017-09-28
FR23C1046I1 (fr) 2024-01-12
AU2012255971A1 (en) 2013-05-02
SMT201700569T1 (it) 2018-01-11
US20180237476A1 (en) 2018-08-23
EP2707385A1 (en) 2014-03-19
US20250042951A1 (en) 2025-02-06
CA2835644C (en) 2021-06-15
US20220332766A1 (en) 2022-10-20
LT3275892T (lt) 2020-04-10
US12139512B2 (en) 2024-11-12
LT2707385T (lt) 2017-12-11
EP3275892A2 (en) 2018-01-31
RS56748B1 (sr) 2018-03-30
CA2835644A1 (en) 2012-11-22
CN103842374A (zh) 2014-06-04
HUE034673T2 (en) 2018-02-28
JP2014519819A (ja) 2014-08-21
NO2707385T3 (en:Method) 2018-02-17

Similar Documents

Publication Publication Date Title
SG194755A1 (en) Pre-fusion rsv f antigens
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
IN2015MN00139A (en:Method)
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EP2771033A4 (en) PROTEIN FORMULATIONS CONTAINING AMINO ACIDS
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
HK1209768A1 (en) Antibodies to tau
EA201391597A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
WO2013054199A3 (en) Cmv antigens and uses thereof
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
EA201792608A3 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
EP3240798B8 (en) Novel method for efficient purification of human serum albumin
EA201391199A1 (ru) Композиции из hyr1-производных и способы лечения ими
PL3560348T3 (pl) Napój aminokwasowy zawierający allulozę
NZ746677A (en) Novel alpha-1-microglobulin derived proteins and their use
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.